DelveInsight’s ‘Presbyopia Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and Presbyopia Pipeline therapies in various stages of Presbyopia clinical trials development, major pharmaceutical Presbyopia Companies are working to advance the Presbyopia pipeline space and future growth potential of the Presbyopia pipeline domain.
For Presbyopia emerging drugs, the Presbyopia pipeline analysis report provides a 360° view of the Presbyopia pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Presbyopia pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key takeaways from the Presbyopia Pipeline Report
- Over 12+ Presbyopia companies are evaluating 12+ Presbyopia pipeline therapies in various stages of development, and their anticipated acceptance in the Presbyopia market would significantly increase market revenue.
- The leading Presbyopia Companies includes Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.
- Promising Presbyopia Pipeline Therapies includes UNR844-Cl, Prototype of adaptive eyeglasses, LaserACE(R), Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, AGN-190584, EV06 Ophthalmic Solution, CSF-1, and others.
- The Presbyopia Companies and academics that are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The Presbyopia pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.
Request a sample and discover the recent breakthroughs happening in Presbyopia pipeline landscape @ Presbyopia Pipeline Outlook Report
Presbyopia Overview
Presbyopia is a vision condition in which the shape of the crystalline lens of your eye changes. These changes make it difficult to focus on close objects. Presbyopia may seem to occur suddenly, but sight reduction occurs over several years. Presbyopia usually becomes noticeable in the early to mid-40s, but the reduction of your focus starts as early as childhood. Some signs of presbyopia include holding reading materials at arm’s length, blurred vision at normal reading distance and eye fatigue along with headaches when doing close work. Presbyopia happens naturally in people as they age. The eye is not able to focus light directly on to the retina due to the hardening of the natural lens. Aging also affects muscle fibers around the lens making it harder for the eye to focus on up close objects. The ineffective lens causes light to focus behind the retina, causing poor vision for objects that are up close.
Presbyopia Emerging Drugs Profile
- CSF-1: Orasis Pharmaceuticals
CSF-1 is a novel presbyopia corrective eye drop being developed to improve the quality of life for people with presbyopia. CSF-1 is a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle. Clinical trial results to date have demonstrated significant improvements in near vision and an excellent safety profile in people with presbyopia. In the Phase 3 studies, CSF-1 achieved statistically significant distance-corrected near visual acuity (DCNVA) and no loss of 1-line or more in distance or night vision.
- UNR844-Cl: Novartis
UNR844-Cl is an ester of naturally occurring R-lipoic acid and choline. Previously called EV06 ophthalmic solution, UNR844 targets directly the flexibility and accommodative ability of the crystalline lens. It breaks disulfide bonds, which are thought to harden the lens over time. By disrupting these bonds, the lens becomes more elastic and regains some functionality.
Find out more about the Presbyopia Diagnosis and Treatment of patients @ Presbyopia Ongoing Clinical Trials Analysis
Presbyopia Pipeline Therapies and Companies
- Orasis Pharmaceuticals: UNR844-Cl
- Novartis: Prototype of adaptive eyeglasses
- Cellix Bio: LaserACE(R)
- Visus Therapeutics: Phentolamine Ophthalmic Solution 0.75%
- AbbVie: Pilocarpine
- Vyluma: AGN-190584
- Lenz Therapeutics: EV06 Ophthalmic Solution
- Ocuphire Pharma: CSF-1
Presbyopia Pipeline Therapeutics Assessment
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Discover more about the list of Presbyopia FDA-approved drugs for Presbyopia @ Presbyopia Treatment Landscape
Scope of the Presbyopia Pipeline Report
- Coverage- Global
- Presbyopia Companies- Orasis Pharmaceuticals, Novartis (NYSE: NVS), Cellix Bio, Visus Therapeutics, AbbVie (NYSE: ABBV), Vyluma, Lenz Therapeutics, Ocuphire Pharma (NYSE: OCUP), JIXING Pharmaceuticals, Eyenovia (NYSE: EYEN), and others.
- Presbyopia Pipeline Therapies- UNR844-Cl, Prototype of adaptive eyeglasses, LaserACE(R), Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, AGN-190584, EV06 Ophthalmic Solution, CSF-1, and others.
- Presbyopia Pipeline Therapies- Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for Presbyopia Emerging Therapies and Ongoing Clinical Trials; visit @ Presbyopia Emerging Therapies and Key Players
Table of Content
- Introduction
- Presbyopia Executive Summary
- Presbyopia: Overview
- Presbyopia Pipeline Therapeutics
- Presbyopia Pipeline Therapeutic Assessment
- Presbyopia – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- CSF-1: Orasis Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- UNR844-Cl: Novartis
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Presbyopia Key Companies
- Presbyopia Key Products
- Presbyopia- Unmet Needs
- Presbyopia- Market Drivers and Barriers
- Presbyopia- Future Perspectives and Conclusion
- Presbyopia Analyst Views
- Presbyopia Key Companies
- Appendix
For further information on the Presbyopia Pipeline therapeutics, reach out @ Presbyopia Market Drivers and Barriers
Latest Pharmaceuticals Market Research Reports
Radiation Retinopathy Market | Stem Cell Market | UK Healthcare Report | Oncolytic Virus Cancer Therapy Pipeline | Vulvar Cancer Market | Persistent Epithelial Defect Market | Chronic Heart Failure Market | Scabies Market | UK Healthcare Outlook Report | Shingles Market | Medical Marijuana Market | Brucellosis Market
Latest Healthcare Blogs by DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com